Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL
Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.
Source: onclive.com
Stay updated with breaking news from Fl Treatment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.
Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.